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Background: To analyze the expression of karyopherin alpha 2 (KPNA2) in upper tract urothelial carcinoma (UTUC)
and to investigate whether the KPNA2 expression provides additional prognostic information following radical
nephroureterectomy (RNU).
Methods: A tissue microarray (TMA) containing samples from 176 patients with UTUC who underwent RNU at our
institute was analyzed for KPNA2 expression using immunohistochemistry. KPNA2 expression in normal urothelial
cell line and urothelial carcinoma cell lines was evaluated by western blot analysis. Using RNA interference in vitro,
the effects of KPNA2 inhibition on cellular viability, migration and apoptosis were determined.
Results: KPNA2 expression was significantly upregulated in the UTUC samples compared with the adjacent normal
urothelial tissues. High KPNA2 immunoreactivity was identified as a predictor of bladder recurrence (hazard ratio
[HR]: 2.017, 95% CI 1.13-3.61, p = 0.018), poor disease-free survival (DFS, HR: 2.754, 95% CI 1.68-4.51, p = 0.001) and
poor overall survival (OS, HR: 4.480, 95% CI 1.84-10.89, p = 0.001) for patients with UTUC after RNU. Furthermore,
high KPNA2 immunoreactivity was independent of the conventional predictive factors in a multivariate analysis.
Additional in vitro experiments revealed that KPNA2 expression was higher in urothelial carcinoma cell lines than
in normal urothelial cell line. KPNA2 inhibition with a specific siRNA decreased cell viability and migration and
increased apoptosis in urothelial carcinoma cell lines.
Conclusions: KPNA2 is a novel independent prognostic marker for bladder recurrence, DFS and OS of UTUC
patients who have undergone RNU. Moreover, these data suggest that KPNA2 may be a promising therapeutic
target for UTUC.
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Urothelial carcinomas are the fourth most common
tumors after prostate (or breast), lung and colorectal
cancer. This carcinoma is derived from the urothelium
of the upper urinary tract (renal pelvis and ureter) or
lower urinary tract (urinary bladder). In contrast with
bladder urothelial carcinomas, upper urinary tract
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A previous study found that the ratio of urothelial
carcinoma incidence in the renal pelvis, ureter, and
urinary bladder is approximately 3:1:51 [2].Radical
nephroureterectomy (RNU) with excision of the
bladder cuff is the standard procedure for UTUC [3].
However, tumor recurrence remains common; specifically,
the disease recurs in the bladder in 22–47% of UTUC
patients [4]. The clinical characteristics and prognosis are
different for UTUC and bladder cancer. The upper
urinary tract has specific relevant anatomical characteris-
tics, including a thin muscle layer, proximity to the kidney
and rich lymphatic drainage. Tumor invasion mays is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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in UTUC patients. Approximately 60% of UTUCs are in-
vasive at diagnosis, in contrast to only 15-25% of bladder
cancers [5,6].
To date, the prognostic factors for recurrence and
survival of patients after RNU remain unclear, and the
published studies on prognostic factors for UTUC are
limited and conflicting [7-9]. The clinicopathologic
parameters of UTUC, such as tumor stage, histologic
grade, and lymphovascular invasion (LVI), have been
reported as independent predictors of clinical outcome
following radical surgery [10].Some molecular markers,
such as E-cadherin, hypoxia-inducible factor (HIF)-1α,
snail, and Ki67 are also independently associated with
tumor recurrence and poor survival [11]. However, none
of the currently available markers have fulfilled the
clinical and statistical criteria necessary to support their
introduction into daily clinical decision making. Thus,
identifying specific novel genes that can be effectively
used as therapeutic targets and/or prognostic biomarkers
is critical for the treatment of UTUC. However, only a
relatively small number of studies have been completed
to date.
KPNA2 belongs to the karyopherin (importin) family,
which plays a fundamental role in nucleocytoplasmic
transport [12]. Together with importin-β, KPNA2
delivers numerous cargo proteins to the nucleus, as
guided by a nuclear localization signal that may also be
important for oncogenesis [13]. KPNA2 has been identi-
fied and validated as a potential biomarker for many
cancers, such as non-small cell lung cancer [14], breast
cancer [15], ovarian cancer [16], and prostate cancer
[17]. High expression of KPNA2 was investigated as an
independent predictor of poor prognosis in patients with
non–muscle-invasive bladder cancer and in patients with
invasive bladder cancer undergoing radical cystectomy
[18].However, currently it is lack of relevant research
about KPNA2 expression in UTCC .
In the present study, we analyzed the KPNA2
expression in UTUC tissues and the prognostic rele-
vance of KPNA2 expression in patients with UTUC who
had undergone RNU. Additionally, the role of KPNA2 in
the proliferation, migration and apoptosis of urothelial
carcinoma cell lines was analyzed in vitro.
Methods
Patient selection
This study was approved by the Review Board of the
Peking University First Hospital (Beijing, P.R. China).
Informed written consent was obtained from all patients.
We retrospectively analyzed the clinical and pathologic
data from 607 patients who underwent RNU for UTUC
from January 2002 to December 2010 at our institute.176
patients with incomplete follow-up data, Among theremaining 431 patients with complete follow-up data,
255 were excluded from the study: 81 had concomitant/
previous bladder tumors, 45 had bilateral synchronous
UTUC, 34 underwent other surgeries instead of radical
nephroureterectomy, 39 had a follow-up period of less
than 12 months, 48 patients with a tumor less than
1.0 cm (diameter) (not suitable for formation of a tissue
microarray), 8 had a positive surgical margin. At last the
remaining 176 patients were included in this study, 81
cases with open surgery, 95 cases with laparoscopic sur-
gery, All UTUC patients undergoing radical nephroure-
terectomy, not receiving routine lymphadenectomy.
Only for those high risk patients, Such as preoperative
imaging examination suspected lymph node metastasis,
high stage and mulifocality, the routine lymphadenectomy
was performed. None of the included patients received pre-
operative chemotherapy, although postoperative chemo-
therapy or radiotherapy was administered at the time of
recurrence or metastasis. The clinical stage was assigned
using the American Joint Committee on Cancer TNM
Staging System for Renal Pelvis and Ureter Cancer (7th
edition, 2010) [19].
In total, we observed 78 male and 98 female patients
with a median age of 69 years (29–86) and a median
follow-up of 36 months (12–108). The patients went to
follow-up appointments on a routine schedule, including
regular cystoscopy, urine cytology and clinical examina-
tions. Cystoscopy was performed every three months for
the first two years, then cystoscopy intervals were
extended to 1 year thereafter. Chest X-ray, serum creat-
ine, abdominal ultrasound, and computed tomography
were examined at the same time. We defined bladder
recurrence as finding a subsequent bladder tumor
during cystoscopy and confirmed it by pathology. The
time of first bladder recurrence was used as the endpoint
for the study. The follow-up of patients without tumor
recurrence was censored to the date of their last visit. In
case of death not related to the bladder cancer, follow-
up was censored to the date of death. Metastasis or
retroperitoneal recurrence was documented.
Immunohistochemistry (IHC) of tissue microarrays and
scoring
The tissue microarrays were constructed as previously
described [20].IHC was performed on formalin-fixed
paraffin -embedded tissue microarrays (TMAs) sections
that consisted of paired normal and UTUC specimens
from 176 patients. IHC was completed using an SP re-
agent kit (Zhongshan Biotechnology Company, Beijing,
China) according to the manufacturer’s instructions. An
anti-KPNA2 antibody (1:800 Abcam plc, Cambridge,
UK) was used as the primary antibody. For a negative
control of the staining procedure, the primary antibody
was omitted. Two surgical pathologists reviewed and
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without knowledge of the clinical data.
To analyze the KPNA2 staining, the percentage of
cancer cells with nuclear immunoreactivity was quanti-
fied. Based on an analysis of different cut-off levels and
previous studies [18,21], high expression of KPNA2 was
defined as strong nuclear staining in at least 10% of the
carcinoma cells.
Cell lines
The normal urothelial cell line SV-HUC-1 and the
urothelial transitional cell carcinoma cell lines 5637,
RT4, T24, UM-UC-3 and J82 were obtained from the
American Type Culture Collection. SV-HUC-1 was
cultured in Ham’s F-12 medium. The 5637, RT4 and
T24 cells were grown in RPMI 1640 medium. J82 and
UM-UC-3 cells were maintained in DMEM. All culture
media were supplemented with 10% fetal bovine serum
(HyClone) and penicillin sodium (100 U/ml)/strepto-
mycin sulfate (100 μg/ml) (Invitrogen). All cells were
grown in a humidified atmosphere incubator with 5%
CO2 at 37°C.
RNA interference
Cells were transfected using the INTERFERINTM re-
agent (PolyplusTransfection, Strasbourg, France) accord-
ing to the manufacturer’s instructions. A pool of two
sequence-validated and knockdown-warranted KPNA2-




(GenePharma, Shanghai, China). Commercial FAM-
tagged, negative control siRNAs (NC siRNA) (5′-UC
CUCCGAACGUGUCACGUTT-3′,5′-ACGUGACACG
UUCGGAGAATT-3′) (GenePharma) were used as an
efficiency control and as a control for unspecific side
effects. Cell lysates were prepared for western blotting
48 h after transfection to determine the efficiency of
gene expression ablation.
Western blot analysis
Total proteins from cell lines were extracted in lysis
buffer (Thermo Fisher Scientific, Rockford, IL, USA) and
quantified using a BCA protein assay (Thermo Scientific,
Rockford, IL, USA). Each extracted protein sample was
separated by 10% SDS-PAGE. After transferring the sep-
arated proteins to a PVDF membrane (Pall, Pensacola,
FL), the membrane was incubated overnight at 4°C with
antibodies against KPNA2 (Abcam Plc, Cambridge, UK,
1:1000), PARP (CST, Danvers, MA, 1:1000), PCNA
(CST, Danvers, MA, 1:1000), or β-actin (Santa Cruz
Biotechnology, 1:1000). After four washes with TBST,
membranes were incubated with the appropriate HRP-conjugated secondary antibody at 37°C for 1 h. The pro-
tein bands were detected using ImmobilonTM Western
Chemiluminescent HRP substrate (Millipore) and
scanned using GeneSnap (Syngene, Cambridge, UK) ac-
quisition software.
Proliferation assays
The cell proliferation capacity of siRNA-transfected
cultures was determined using Cell Counting Kit-8
solution (Dojindo, Gaithersburg, Kumamoto, Japan)
according to the manufacturer’s protocol. Briefly,
cells were seeded at a concentration of 5 × 103 cells/
100 μl/well in 96-well culture plates and treated with
10 μl/well of Cell Counting Kit-8H solution during
the last 2 h of culturing. The optical density of the
wells was measured at 450 nm using a Multiscan
microplate spectrophotometer (Thermo LabSystems,
Milford, MA).
Migration assay
Cell migration was assessed using a Boyden chamber
assay. A total of 5 × 104 cells in 100 μl serum-free
medium were seeded onto the upper chambers of a 24-
well Boyden Chamber insert (Costar #3422) with
uncoated 8-μm pores. Medium with 10% FBS was added
to the lower chambers as a chemoattractant. After 24 h
of incubation, cells remaining on the upper surface of
the membrane were removed with a cotton swab, and
cells that migrated through the membrane filter were
fixed with 4% paraformaldehyde, stained with 0.1%
crystal violet, and photographed under a microscope
(Olympus BX40 with a DP70 digital camera). The mi-
grating cells were manually counted per high-power field
for each condition, and five fields were randomly
selected per membrane.
Apoptosis assay
Apoptosis was evaluated by using an Annexin-V/PI
apoptosis detection kit (KeyGen Biotech, Nanjing,
China) following the manufacturer’s instructions. Cells
were cultured in 6-well plates at a concentration of 2-
3 × 105 cells/2 ml/well and transfected with siRNA.
Cells were collected 48 h after transfection and then
resuspended in 500 μl binding buffer, followed by the
addition of 5 μl Annexin V-FITC and 5 μl PI dye. After
an incubation of 10–15 min at room temperature in the
dark, cells were analyzed using a BD FACStar flow
cytometer (Becton Dickinson, San Jose, CA).
Mitochondrial membrane potential (Δψm) assay
ΔΨm was estimated using a mitochondrial membrane
sensor kit containing the cationic lipophilic fluoro-
chrome JC-1 dye (KeyGEN Biotech, Nanjing, China)
according to the manufacturer’s protocol. Briefly, 48 h
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suspended in 500 μl JC-1 working solution for 20–30 min.
Next, the cells were analyzed using a BD FACStar flow
cytometer (Becton Dickinson, San Jose, CA).
Caspase 3/7 activity assay
A total of 5 × 103 cells were seeded in 96-well cell
culture plates. After a 48 h siRNA treatment, apoptosis
rates were measured based on the activation of effector
caspases 3 and 7 using the Caspase-GloTM3/7 Substrate
kit (Promega, Mannheim, Germany) according to the
manufacturer’s instructions. All samples were performed
in triplicate.
Statistical analyses
A two-sided Fisher’s exact test or Pearson’s 2-sided χ2 test
was used to study significant differences between immu-
nohistochemical and clinicopathologic data. To compare
two independent samples, the nonparametric Mann–
Whitney test was used. Survival curves for patients with
low or high KPNA2 expression were plotted using the
Kaplan-Meier method, with log-rank tests for statistical
significance. Uni- and multi-variable Cox regression ana-
lyses were used to test the prognostic relevance of clinico-
pathologic/immunohistochemical data. Only predictive
factors that were significant in the univariate analysis were
used in the multivariate analysis (Cox’s proportional
hazards model). SPSS version 17.0 (SPSS) was used to
complete the statistical analysis. P < 0.05 was considered
significant.
Results
Correlation between KPNA2 expression and
clinicopathologic features of UTUC
KPNA2 expression was investigated using immunohis-
tochemical analysis of a TMAs containing 176 paired
UTUC and adjacent normal specimens. Representative
KPNA2 staining is shown in Figure 1A. KPNA2 expres-
sion is significantly higher in UTUC than in adjacent
normal tissues. Table 1 lists the clinicopathologic fea-
tures of patients and their correlation with KPNA2
expression in UTUC specimens. KPNA2 expression
was significantly associated with sex (P = 0.038), T stage
(P < 0.001) and G grade (P < 0.001).
KPNA2 expression is a prognostic marker in UTUC
patients after RNU
Using the log-rank test, Kaplan-Meier survival curves
show an inverse correlation between KPNA2 expression
and the patient survival rate (Figure 1B). The 5-year
bladder recurrence-free survival rate for KPNA2-low
expression patients (71.9%) was significantly higher
than that for KPNA2-high expression patients (59.4%)(P = 0.047). The 5-year disease-free survival (DFS) rate
for KPNA2-low expression patients (61.5%) was also
significantly higher than the DFS rate for KPNA2-high
expression patients (35.1%) (P = 0.001). The 5-year
overall survival (OS) rate for KPNA2-low expression
patients (88.2%) was also significantly higher than the
OS rate for KPNA2-high expression patients (77.3%)
(P = 0.005).High expression of KPNA2 is an independent prognostic
factor for poor bladder recurrence-free survival of UTUC
patients after RNU
Of the 176 patients, 50 patients (28.4%) developed
subsequent bladder tumors at a median interval of
29 months (range: 2–99) after RNU. According to a uni-
variate analysis, the predictive factors for bladder recur-
rence were age (P = 0.042), sex (P = 0.014), tumor
location (P = 0.007), tumor side (P = 0.046), tumor
multiplicity (P = 0.001), tumor stage (0.039) and KPNA2
expression (P = 0.001). The multivariate analysis re-
vealed that sex (P = 0.017), tumor location (P = 0.015),
tumor multiplicity (P = 0.002) and KPNA2 expression
(P = 0.018) were significantly associated with bladder
recurrence (Table 2) and were independent risk factors
for bladder recurrence.However, tumor side was mar-
ginally significant (P = 0.057) in the multivariate ana-
lysis. Neither tumor stage nor tumor grade was an
independent risk factor for bladder recurrence.High expression of KPNA2 is an independent prognostic
factor for the poor DFS and OS of UTUC patients after
RNU
Of the 176 patients, 106 patients (64.2%) were disease-
free and alive at a median follow-up of 39 months
(range: 13–99). A total of 50 patients (28.4%) devel-
oped bladder recurrence, 12 patients (6.82%) devel-
oped non-bladder recurrence, and 20 patients (11.4%)
developed metastasis. A total of 26 patients (14.8%)
died after a median period of 20 months (range: 12–
98). A univariate Cox regression analysis (Table 3) re-
vealed that male sex (P = 0.004), tumors located in the
ureter (P = 0.015), multiple tumor foci (P = 0.009),high
stage(P = 0.012) and high KPNA2 expression (P < 0.001)
were highly associated with a shorter DFS. In the
multivariate Cox regression analysis, only high KPNA2 ex-
pression (P = 0.001), male gender (P = 0.002), multiple
tumor foci (P = 0.013) and tumor stage(p = 0.022) remained
significant. Male sex (P = 0.001), a tumor diameter larger
than 3.5 cm (P = 0.005),,high stage(P = 0.001) and high
KPNA2 expression (P = 0.001) were significantly associ-
ated with shorter OS both in the uni- and multi-
variable Cox regression analyses (in Table 4).
Figure 1 KPNA2 expression in normal and UTUC specimens and its correlation with survival. (A) Representative micrograph of IHC staining for KPNA2
in UTUC and adjacent normal tissues (Original magnification: ×100; ×200). (B) Kaplan–Meier curves of bladder recurrence-free survival, disease-free
survival and overall survival of UTUC patients with high KPNA2 expression versus patients with low KPNA2 expression.
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urothelial carcinoma cells
We employed in vitro techniques to investigate the
mechanism by which KPNA2 contributes to UTUC
malignancy. Consistent with the IHC staining results
from UTUC specimens, western blot analysis showed
that the KPNA2 level was very low in normal human
urinary tract epithelial cell line SV-HUC-1, while cancer
cell lines derived from low-grade (5637), superficial
(RT4), and invasive (T24, J82, UM-UC-3, and EJ)
urinary tract TCC showed increased levels of KPNA2
(Figure 2A). The T24 and J82 cell lines were selected for
subsequent analysis because of their high KPNA2
expression levels among the urinary tract TCC cell lines.
siRNA technology was used to knockdown KPNA2
in T24 and J82 cells. Western blot analysis showedthat following KPNA2-directed siRNA transfection,
KPNA2 protein expression was significantly lower
than in cells transfected with control RNA (Figure 2B).
Thus, the KPNA2-directed siRNA was effective at si-
lencing KPNA2 expression and was used for subsequent
experiments.
Following knockdown of KPNA2, the viability of the
cells was significantly lower than that of control cells,
as assessed by a proliferation assay (Figure 2C and D).
T24 and J82 cell migration was assayed by the Boyden
chamber assay. As shown in Figure 2E and F, the num-
ber of migrating cells was significantly lower in KPNA2
knockdown cells than in control cells. These studies
showed that knockdown of KPNA2 resulted in de-
creased proliferation and migration of urothelial carcin-
oma cells.
Table 1 Correlation between KPNA2 expression and clinicopathologic characteristics of UTUC patients after RNU
KPNA2 immunoreactivity
Variable Case No. Low (N = 101) High (N = 75) P*
Sex 0.038
Male 78 48 30
Female 98 53 45
Age (y) 0.95
≥70 84 48 36
<70 92 53 39
BMI (kg/m2) 0.26
>27 37 24 13
27-22 81 46 35
<22 58 31 27
Tumor size (cm) 0.46
≥3.5 81 41 40
<3.5 95 60 35
T stage <0.001
Ta-T1 61 48 13
T2 70 36 34
T3 42 17 25
T4 3 0 3
Pathologic lymph node stage 0.25
N0 168 98 70
N+ 8 3 5
G grade <0.001
G1 3 3 0
G2 105 77 28
G3 68 21 47
eGFR (ml/min/1.73 m2)# 0.83
≥60 77 48 29
60-15 90 49 41
<15 9 4 5
Hydronephrosis 0.24
Absent 70 46 24
Present 106 65 41
Location 0.30
81 50 31
Renal pelvis Proximal 6 5 1
Middle 17 9 8
Distal ureter 52 26 26
Multiple 20 11 9
Side 0.95
Left 82 49 33
Right 94 52 42
Tumor multiplicity 0.99
Shi et al. BMC Cancer  (2015) 15:380 Page 6 of 11
Table 1 Correlation between KPNA2 expression and clinicopathologic characteristics of UTUC patients after RNU
(Continued)
Single tumor focus 121 69 52
Multiple tumor foci 55 32 23
Tumor configuration 0.53
Papillary 140 82 58
Nonpapillary 36 19 17
*Mann–Whitney test for the comparison between two groups or Kruskal-Wallis test for more than two groups.
# Estimated glomerular filtration rate (eGFR) was calculated using the re-expressed Modification of Diet in Renal Disease (MDRD) formulas for the Chinese population.
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carcinoma cells
To assess whether increased apoptosis was involved in
the significant decrease in cell viability following
KPNA2 knockdown, we employed an apoptosis assay
using Annexin V-FITC and propidium iodide double
staining, followed by flow cytometry analysis. As shown
in Figure 3A and B, the apoptosis rate in KPNA2
knockdown cells was significantly higher than in con-
trol cells. Consistently, KPNA2 knockdown induced a
significant increase in the disruption of the mitochon-
drial Δψm compared with control cells, which was
suggested to be an early event in the apoptotic process
[22] [12766472] (Figure 3C, D).Furthermore, the activity
of caspase-3 and −7, which are executioners of apoptosis,
was also significantly increased after KPNA2 knockdown
(Figure 3E). Consistently, the cleavage of PARP, a
marker of apoptosis, was significantly increased in
KPNA2 knockdown cells as demonstrated by a western
blot assay (Figure 3F). The expression of PCNA, a marker
of proliferation, was decreased in KPNA2 knockdownTable 2 Predictive factors for bladder recurrence in UTUC pat
Variable Characteristics Univariat
HR (95%
Age (y) ≥70 vs <70 0.969 (0.9
Sex Male vs female 2.077 (1.1
BMI (kg/m2) ≥25 vs <25 0.791 (0.4
Tumor side Left vs Right 1.853 (1.0
Tumor location Ureter vs Pelvis 2.873 (1.3
Tumor multiplicity Multiple vs Single 2.770 (1.5
Tumor size (cm) ≥3.5 vs <3.5 0.590 (0.3
Tumor configuration Nonpapillary vs Papillary 0.592 (0.2
T stage T2-T4 vs Ta-T1 0.951 (0.9
G grade High vs Low 0.696 (0.3
eGFR (ml/min/1.73 m2) <60 vs ≥60 0.752 (0.3
Hydronephrosis Present vs Absent 0.595 (0.2
Lymph node stage N+ vs N0 0.226 (0.0
KPNA2 expression High vs Low 3.052 (1.6
HR, hazard radio; CI, confidence interval; BMI, body mass index; eGFR, estimated glocells (Figure 3F). Taken together, these data show that
KPNA2 knockdown activated the apoptosis pathway and
decreased the proliferation of urothelial carcinoma cells.
Discussion
To the best of our knowledge, this is the first study in
which the relationships between expression of KPNA2
and the most clinically relevant features of UTUCs were
evaluated. We demonstrated that KPNA2 was signifi-
cantly upregulated in UTUC specimens. Moreover, high
nuclear KPNA2 immunoreactivity was identified as a
novel predictor of bladder recurrence and poor DFS and
OS of UTUC patients after RNU, and its predictive
ability was independent of the conventional predictive
factors such as sex, tumor location, tumor size, and
tumor multiplicity. Additionally, KPNA2 knockdown re-
sulted in decreased cell proliferation and migration and
increased apoptosis in urothelial carcinoma cells.
The karyopherins are an evolutionarily conserved
family of transport factors that mediate the nucleocyto-
plasmic transport of large complexes (>40 kDa) [23].ients after RNU
e Multivariate
CI) P value HR (95%CI) P value
41-0.999) 0.042* 0.977 (0.953-1.003) 0.080
57-3.729) 0.014* 1.980 (1.127-3.480) 0.017
29-1.458) 0.452
10-3.401) 0.046* 1.732 (0.984-3.049) 0.057
42-6.151) 0.007 2.020 (1.147-3.560) 0.015
21-5.046) 0.001 2.431 (1.388-4.261) 0.002
11-1.119) 0.106
60-1.350) 0.212





00-5.822) 0.001 2.017 (1.126-3.612) 0.018
merular filtration rate.
Table 3 Predictive factors for disease-free survival of UTUC patients after RNU
Variable Characteristics Univariate Multivariate
HR (95%CI) P value HR (95%CI) P value
Age (y) ≥70 vs <70 0.996 (0.969-1.023) 0.761
Sex Male vs female 2.079 (1.268-3.409) 0.004 2.171 (1.340-3.516) 0.002
BMI (kg/m2) ≥25 vs <25 1.078 (0.648-1.791) 0.773
Tumor side Left vs Right 1.293 (0.782-2.137) 0.316
Tumor location Ureter vs Pelvis 2.243 (1.171-4.296) 0.015 1.526 (0.951-2.448) 0.080
Tumor multiplicity Multiple vs Single 1.954 (1.180-3.234) 0.009 1.820 (1.132-2.925) 0.013
Tumor size (cm) ≥3.5 vs <3.5 1.293 (0.782-2.137) 0.316
Tumor configuration Nonpapillary vs Papillary 0.722 (0.369-1.414) 0.343
T stage T2-T4 vs Ta-T1 2.041 (1.173-4.195) 0.012 1.836 (1.132-3.125) 0.022
G grade High vs Low 0.831 (0.471-1.467) 0.523
eGFR (ml/min/1.73 m2) <60 vs ≥60 0.822 (0.483-1.400) 0.471
Hydronephrosis Present vs Absent 0.552 (0.288-1.057) 0.073
Lymph node stage N+ vs N0 1.437 (0.458-4.512) 0.535
KPNA2 expression High vs Low 3.424 (1.972-5.944) 0.000 2.754 (1.683-4.506) 0.001
HR, hazard radio; CI, confidence interval; BMI, body mass index; eGFR, estimated glomerular filtration rate.
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port factors) and exportins (export factors). To date,
approximately 22 importin β proteins and 6 importin α
proteins have been identified in human cells [24]. Impor-
tin α/importin β heterodimers recognize cargo proteins
based on their nuclear localization signal and mediate
the classical nuclear protein import pathway [25].
KPNA2 (karyopherin α2) is a member of the karyo-
pherin α family. It deliversnumerouscargoproteins to theTable 4 Predictive factors for overall survival of UTUC patient
Variable Characteristics Univariate
HR (95%C
Age (y) ≥70 vs <70 1.036 (0.98
Sex Male vs female 4.195 (1.63
BMI (kg/m2) ≥25 vs <25 0.933 (0.37
Tumor side Left vs Right 0.482 (0.17
Tumor location Ureter vs Pelvis 2.026 (0.52
Tumor multiplicity Multiple vs Single 1.041 (0.39
Tumor size (cm) ≥3.5 vs <3.5 4.245 (1.52
Tumor configuration Nonpapillary vs Papillary 1.860 (0.67
T stage T2-T4 vs Ta-T1 4.172 (1.60
G grade High vs Low 0.932 (0.36
eGFR (ml/min/1.73 m2) <60 vs ≥60 1.247 (0.43
Hydronephrosis Present vs Absent 1.081 (0.29
Lymph node stage N+ vs N0 3.206 (0.71
KPNA2 expression High vs Low 3.443 (1.27
HR, hazard radio; CI, confidence interval; BMI, body mass index; eGFR, estimated glonucleusandissubsequentlyshuttledbacktothecytoplasmic
compartmentsthroughbindingtoRan-GTP[26].
Identifying risk factors or biomarkers for bladder
recurrence of UTUC would contribute greatly to the
management of this disease due to its high incidence
even after standard surgical procedures. However, there
were no well-established prognostic factors until
recently. Li and Chen et al. reported that male sex is an
independent risk factor for bladder recurrence ofs after RNU
Multivariate
I) P value HR (95%CI) P value
1-1.095) 0.207





6-11.803) 0.006 3.680 (1.495-9.056) 0.005
6-5.116) 0.229





1-9.329) 0.015 4.480 (1.844-10.887) 0.001
merular filtration rate.
Figure 2 KPNA2 expression in urinary tract TCC cell lines and KPNA2 knockdown in vitro. (A) Western blot analyses of KPNA2 expression in
normal and TCC cell lines of the urinary tract. (B) Western blot analyses of KPNA2 expression in T24 and J82 cells transfected with a control or
KPNA2-directed siRNA. (C, D) Proliferation assay results from J82 and T24 cells transfected with a control or KPNA2-directed siRNA. (E) Representative
images of migrating cells evaluated by the Boyden chamber assay (Original magnification: ×100). (F) The quantification results for migrating cells are
presented as the mean ± SD of three independent experiments, with five random fields counted per chamber. *P < 0.05.
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[4,27]. Ureteric tumor location is also an independent
predictor of bladder recurrence [28,29] and the develop-
ment of muscle-invasive bladder cancer after RNU [30].
The tumor multiplicity of UTUC was shown to inde-
pendently influence bladder recurrence after RNU in
multiple studies [31]. In our study, KPNA2 immunore-
activity was demonstrated to be a prognostic factor for
bladder recurrence of primary UTUC after RNU in the
multivariate Cox regression analysis after excluding
patients with bilateral synchronous UTUCs and those
with previous or concomitant bladder tumors. KPNA2
immunoreactivity was independent of conventional
factors, such as sex, tumor multiplicity, and tumor loca-
tion. To date, none of the published biomarkers for
UTUC has been utilized in clinical practice. The
description of KPNA2 as an independent prognostic
factor for bladder recurrence and survival clearly sup-
ports its expression as a promising prognosis biomarker
for UTUC.
KPNA2 may affect oncogenesis by mediating the sub-
cellular localization of cancer-associated cargo proteins.
For example, KPNA2 controls the import of NBS1, a key
component of the MRE11/RAD50/NBS1 complex that is
involved in processing double-strand breaks, DNA re-
combination, and the maintenance of genomic stability
[32]. NBS1 plays opposing roles in carcinogenesis basedon its subcellular localization and is mainly regulated by
KPNA2. Cytoplasmic NBS1 promotes tumorigenesis by
activating the PI3-kinase/AKT pathway, while nuclear
NBS1 acts as a tumor suppressive protein involved in
DNA repair and cell cycle checkpoint control [33]. The
NF-κB family member p65 (RelA) is also a cargo pro-
tein of KPNA2 [34]. Nuclear translocation of NF-κB
p65 can promote carcinogenesis by increasing prolifera-
tion and migration and by activating the antiapoptotic
pathway in cancer cells. Moreover, NF-κB p65 nuclear
immunoreactivity is increased in UTUC tissues and is
an independent predictor for disease-free survival and
OS [35]. Therefore, the inhibited proliferation and mi-
gration and the increased apoptosis after KPNA2 silen-
cing in our in vitro model may be due to the decreased
nuclear translocation of NF-κB p65 by KPNA2. How-
ever, further studies are needed to fully illustrate the
reciprocal effects between KPNA2 expression and p65-
signaling in UTUC.
Our study has some limitations. First, it is limited by
its single-institution and retrospective study design
and the relatively short follow-up duration. Future
prospective validation studies should be performed
across multiple centers. Second, the present study
does not include information on other risk factors,
such as concomitant carcinoma in situ, urine cytology
or surgical modality, which may improve the accuracy
Figure 3 KPNA2 knockdown induces apoptosis in urothelial carcinoma cells. (A,B) The apoptosis rate, as evaluated by flow cytometry analysis
using Annexin-V/PI staining. (C,D) The percentage of cells with mitochondrial Δψm disruption, as evaluated by flow cytometry analysis using the
JC-1 dye. (E) Caspase 3/7 activity of T24 and J82 cells transfected with control or KPNA2-directed siRNA. The data in (A–E) represent the mean ±
SD of three independent tests performed in triplicate. *P < 0.05. (F) Western blot analysis of PARP cleavage and PCNA expression in control and
KPNA2 knockdown cells.
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in the production of tissue microarrays, because of the
limitations of pathologic specimens, we did not choose
the tumor specimens whose diameter less than 1 cm,
and that maybe cause selection bias.Additionally, our
study focused on immunoreactivity of KPNA2 by IHC,
thus, we did not fully evaluate the associations between
KPNA2 immunoreactivity and other reported biomarkers,
such as serum C-reactive protein levels [36], or KPNA2
cargo proteins, such as NF-κB p65 or NBS1.
Conclusions
In conclusion, our results demonstrate that KPNA2 is
overexpressed in UTUC specimens. Moreover, in this
study, high expression of KPNA2 was a novel inde-
pendent predictor for bladder recurrence and poor DFS
and OS of UTUC patients after RNU.Further functional
studies and prospective validation studies are needed to
determine whether KPNA2 is a suitable therapeutic
target or whether its high expression can be used as a
novel risk factor when selecting UTUC patients who re-
quire more aggressive treatment regimens in the clinic.Ethical statement
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